Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE 2017-18 Annual Report Analysis
Sat, 31 Mar

CADILA HEALTHCARE has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

CADILA HEALTHCARE Income Statement Analysis

  • Operating income during the year rose 29.7% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 48.8% YoY during the fiscal. Operating profit margins witnessed a fall and down at 23.8% in FY18 as against 20.7% in FY17.
  • Depreciation charges increased by 44.3% and finance costs increased by 75.6% YoY, respectively.
  • Other income declined by 9.6% YoY.
  • Net profit for the year grew by 17.8% YoY.
  • Net profit margins during the year declined from 16.2% in FY17 to 14.7% in FY18.

CADILA HEALTHCARE Income Statement 2017-18

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Net Sales Rs m 91,807 119,050 29.7%
Other income Rs m 1,471 1,330 -9.6%
Total Revenues Rs m 93,278 120,380 29.1%
Gross profit Rs m 19,012 28,286 48.8%
Depreciation Rs m 3,733 5,388 44.3%
Interest Rs m 631 1,108 75.6%
Profit before tax Rs m 16,119 23,120 43.4%
Tax Rs m 1,289 5,644 337.9%
Profit after tax Rs m 14,830 17,476 17.8%
Gross profit margin % 20.7 23.8
Effective tax rate % 8.0 24.4
Net profit margin % 16.2 14.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF

CADILA HEALTHCARE Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 61 billion as compared to Rs 53 billion in FY17, thereby witnessing an increase of 14.6%.
  • Long-term debt stood at Rs 26 billion as compared to Rs 25 billion during FY17, a growth of 3.5%.
  • Current assets rose 37% and stood at Rs 82 billion, while fixed assets rose 7% and stood at Rs 89 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 171 billion as against Rs 143 billion during FY17, thereby witnessing a growth of 20%.

CADILA HEALTHCARE Balance Sheet as on March 2018

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Networth Rs m 69,600 87,445 25.6
 
Current Liabilities Rs m 53,058 60,830 14.6
Long-term Debt Rs m 24,684 25,551 3.5
Total Liabilities Rs m 143,252 171,407 19.7
 
Current assets Rs m 60,223 82,297 36.7
Fixed Assets Rs m 83,029 89,110 7.3
Total Assets Rs m 143,252 171,407 19.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



CADILA HEALTHCARE Cash Flow Statement Analysis

  • CADILA HEALTHCARE's cash flow from operating activities (CFO) during FY18 stood at Rs 9 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -10 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs 515 million on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -29 million from the Rs 8 billion net cash flows seen during FY17.

CADILA HEALTHCARE Cash Flow Statement 2017-18

Particulars No. of months 12 12 % Change
Year Ending Mar-17 Mar-18
Cash Flow from Operating Activities Rs m 13,117 9,193 -29.9%
Cash Flow from Investing Activities Rs m -28,719 -9,737 -
Cash Flow from Financing Activities Rs m 23,158 515 -97.8%
Net Cash Flow Rs m 7,556 -29 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for CADILA HEALTHCARE

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 17.1, an improvement from the EPS of Rs 14.5 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 378.7, stands at 22.2 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 5.4 times, while the price to sales ratio stands at 4.0 times.
  • The company's price to cash flow (P/CF) ratio stood at 20.6 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Sales per share (Unadj.) Rs 89.7 116.3
TTM Earnings per share Rs 14.5 17.1
Diluted earnings per share Rs 14.5 17.1
Price to Cash Flow x 24.4 20.6
TTM P/E ratio x 32.9 22.2
Price / Book Value ratio x 5.6 5.4
Market Cap Rs m 391,582 470,666
Dividends per share (Unadj.) Rs 3.2 3.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for CADILA HEALTHCARE

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.4x during FY18, from 1.1x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 21.9x during FY18, from 26.5x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 20.0% during FY18, from 21.3% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 21.4% during FY18, from 17.8% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 10.8% during FY18, from 10.8% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Current ratio x 1.1 1.4
Debtors’ Days Days 91 98
Interest coverage x 26.5 21.9
Debt to equity ratio x 0.4 0.3
Return on assets % 10.8 10.8
Return on equity % 21.3 20.0
Return on capital employed % 17.8 21.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how CADILA HEALTHCARE has performed over the last 5 years, please visit here.

CADILA HEALTHCARE Share Price Performance

Over the last one year, CADILA HEALTHCARE share price has moved down from Rs 443.3 to Rs 378.7, registering a loss of Rs 64.6 or around 14.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,157.6 (down 1.1%). Over the last one year it has moved down from 15,312.4 to 13,157.6, a loss of 2,155 points (down 14.1%).

Overall, the S&P BSE SENSEX is up 12.1% over the year.

(To know more, check out historical annual results for CADILA HEALTHCARE and quarterly results for CADILA HEALTHCARE)

Annual Report FAQs

What is the current share price of CADILA HEALTHCARE?

CADILA HEALTHCARE currently trades at Rs 936.3 per share. You can check out the latest share price performance of CADILA HEALTHCARE here...

What was the revenue of CADILA HEALTHCARE in FY18? How does it compare to earlier years?

The revenues of CADILA HEALTHCARE stood at Rs 120,380 m in FY18, which was up 29.1% compared to Rs 93,278 m reported in FY17.

CADILA HEALTHCARE' revenue has grown from Rs 71,616 m in FY14 to Rs 120,380 m in FY18.

Over the past 5 years, the revenue of CADILA HEALTHCARE has grown at a CAGR of 13.9%.

What was the net profit of CADILA HEALTHCARE in FY18? How does it compare to earlier years?

The net profit of CADILA HEALTHCARE stood at Rs 17,476 m in FY18, which was up 17.8% compared to Rs 14,830 m reported in FY17.

This compares to a net profit of Rs 19,213 m in FY16 and a net profit of Rs 11,861 m in FY15.

Over the past 5 years, CADILA HEALTHCARE net profit has grown at a CAGR of 20.2%.

What does the cash flow statement of CADILA HEALTHCARE reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of CADILA HEALTHCARE reveals:

  • Cash flow from operations decreased in FY18 and stood at Rs 9,193 m as compared to Rs 13,117 m in FY17.
  • Cash flow from investments increased in FY18 and stood at Rs -9,737 m as compared to Rs -28,719 m in FY17.
  • Cash flow from financial activity decreased in FY18 and stood at Rs 515 m as compared to Rs 23,158 m in FY17.

Here's the cash flow statement of CADILA HEALTHCARE for the past 5 years.

(Rs m)FY14FY15FY16FY17FY18
From Operations9,0289,93618,93513,1179,193
From Investments-4,380-4,647-8,635-28,719-9,737
From Financial Activity-5,287-3,511-9,34823,158515
Net Cashflow-6391,7789917,556-29

What does the Key Ratio analysis of CADILA HEALTHCARE reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of CADILA HEALTHCARE reveals:

  • Operating profit margins witnessed a fall and down at 23.8% in FY18 as against 20.7% in FY17.
  • Net profit margins declined from 16.2% in FY17 to 14.7% in FY18.
  • Debt to Equity ratio for FY18 stood at 0.3 as compared to 0.4 in FY17.

Here's the ratio/financial analysis of CADILA HEALTHCARE for the past 5 years.

 FY14FY15FY16FY17FY18
Operating Profit Margin (%)16.620.525.220.723.8
Net Profit Margin (%)11.814.020.816.214.7
Debt to Equity Ratio (x)0.40.30.20.40.3

Read: Latest Annual Report Analysis of ZYDUS LIFESCIENCES

 

Equitymaster requests your view! Post a comment on "CADILA HEALTHCARE 2017-18 Annual Report Analysis". Click here!